Immunology Investor Event
sanofi
DupixentⓇ China: 'All In' to build a Blockbuster
High unmet need in AD¹
Major Milestones Achieved - in less than 2 years
Atopic Dermatitis launch indication
~2-5% of
adult urban population
Prevalence
- July 2020
-
fastest BLA approval in China
- December 2020 - Inclusion in NRDL
- September 2021
-
Approval in adolescent AD indication
~9M
~900K
Treated moderate-to-
severe
Accessible, affordable
(biologic eligible)
of which ~300K
2022 estimate
>30K
Patients treated with
DupixentⓇ to date
- February 2022 - Approval in children 6Y+
Launch execution
Coverage in >3,000 hospitals and >15,000 HCPs
>1,000 hospitals listed
- 1/3 of accessible affordable market unlocked
Planned indications and launch year
- AD infant- 2023
- Asthma - 2024
- COPD - 2025
1 Based on China KOL estimates and publications as well as internal analysis; this is based on total urban China population (approximately 60% of total population)
24
Immunology DayView entire presentation